Skip to content

Biodesix, Inc. BDSX EBITDA margin

EBITDA margin at other companies

NeoGenomics logo
NeoGenomicsNEO
-5.3%-85.9pp
Veracyte logo
VeracyteVCYT
18.3%+8.1pp
Adaptive Biotechnologies logo
Adaptive BiotechnologiesADPT
-10.1%-4.6pp
Personalis, Inc. logo
Personalis, Inc.PSNL
-143.7%-918pp
Guardant Health logo
Guardant HealthGH
-37.8%-8.5pp
GeneDx Holdings logo
GeneDx HoldingsWGS
-9%

Other financials

Income statement

See full
Revenue$25.6M+42.3%
Operating income-$6.2M+32.1%
Net income-$7.8M+29.8%
EPS (diluted)-$0.81+46.7%

Balance sheet

See full
Cash & equivalents$25.6M+45.3%
Total debt$71.6M+15.0%
Total equity$9.1M-17.4%
Total assets$94.6M+9.7%

Cash flow

See full
Operating cash flow-$10.2M-18.2%
CapEx$81.0K+9.5%
Free cash flow-$10.2M-18.1%

Valuation

See full
Market cap$233.52M+476%
Enterprise value$279.56M+204%
P/S2.4×+1.9×

Profitability

See full
Operating margin-26%-7.5pp
Net margin-33.3%-9.3pp
FCF margin-26.8%-9.6pp

Returns & leverage

See full
Return on equity-316.5%
Debt / equity7.8×+2.2×
Current ratio2.8×+0.6×

Where this comes from

Calculated from Biodesix, Inc.’s reported figures.

Based on trailing twelve months.

The official record: Biodesix, Inc.’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →

Ask your AI about Biodesix, Inc.'s ebitda margin.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Biodesix, Inc.'s EBITDA margin?
Biodesix, Inc. (BDSX) reported EBITDA margin of -20.1% in Q1 2026.
How has Biodesix, Inc.'s EBITDA margin changed year-over-year?
Biodesix, Inc.'s EBITDA margin increased by 44.2% year-over-year, from -36% to -20.1%.
What is the long-term trend for Biodesix, Inc.'s EBITDA margin?
Over 5 years (2020 to 2025), Biodesix, Inc.'s EBITDA margin has grown at a -10.6% compound annual growth rate (CAGR), from -44% to -25.1%.
What does EBITDA margin mean?
EBITDA (earnings before interest, taxes, depreciation, and amortization) as a percentage of revenue, trailing twelve months. A proxy for cash operating profitability that strips out capital-structure and non-cash charges.